Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Gynecologic Oncology|August 14, 2012
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancerKimberly K Leslie, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology|October 16, 2022
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trialJohn H Farley, William E Brady, David O'Malley, et al.
Gynecologic Oncology|May 21, 2018
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group studyVivian E von Gruenigen, Helen Q Huang, David Cella, et al.
Journal of the National Cancer Institute|June 20, 2015
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 TrialAshley S Felix, Louise A Brinton, D Scott McMeekin, et al.
Gynecologic Oncology|December 25, 2012
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group studyEdwin A Alvarez, William E Brady, Joan L Walker, et al.
Gynecologic Oncology|March 15, 2013
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trialLouise A Brinton, Ashley S Felix, D Scott McMeekin, et al.
Gynecologic Oncology|October 12, 2016
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary studyArlene E Garcia-Soto, James J Java, Wilberto Nieves Neira, et al.
Journal of Clinical Microbiology|February 17, 2012
Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimensNicolas Wentzensen, Patti E Gravitt, Rodney Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancerCatherine Lhommé, Florence Joly, Joan L Walker, et al.
Gynecologic Oncology|May 10, 2017
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group StudyShannon Grabosch, George Tseng, Robert P Edwards, et al.
Pageof 15